General Information of Drug (ID: DMKETFV)

Drug Name
SMER3 Drug Info
Synonyms
67200-34-4; SMER 3; 9H-Indeno[1,2-e][1,2,5]oxadiazolo[3,4-b]pyrazin-9-one; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one; SMER-3; C11H4N4O2; LSM-42773; 9H-Indeno-[1,2-e]-[1,2,5]-oxadiazolo-[3,4-b]-pyrazin-9-one; indeno[2,3-b]1,2,5-oxadiazolo[3,4-e]pyrazin-5-one; 2-Oxa-1,3,4,10-tetraaza-cyclopenta[b]fluoren-9-one; SMER3(SMER 3); Oprea1_175199; Oprea1_783821; SCHEMBL7984580; CHEMBL3589013; ZINC27763; AOB5567; DTXSID40340952; CHEBI:131171; BDBM188214; HMS1607O01; BCP14360; 2188AH; MFCD00451458; SBB000632; STK120842; SMER3, >=98% (HPLC); AKOS000479457; MCULE-1070513713; AS-55891; ST000573; DB-073845; FT-0701471; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one; Indeno[1,2-b]furazano[3,4-E]pyrazin-9-one,; US9073941, 28; US9073941, 30; SR-01000388225; SR-01000388225-1; Q27224946; 9H-Indeno[1,2-b][1,2,5]oxadiazolo[3,4-E]pyrazin-9-one #
Cross-matching ID
PubChem CID
568763
ChEBI ID
CHEMBL131171
CAS Number
CAS 67200-34-4
TTD Drug ID
DHD79B

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
Rheumatoid arthritis 2.14 0.00e+0 78/93 (83.87%) MMP1;JUN;HLA-DQA1;...
Legionellosis 2.13 0.00e+0 51/57 (89.47%) HSPA6;HSPA1A;CXCL8;...
Ferroptosis 2.09 0.00e+0 36/41 (87.8%) HMOX1;MAP1LC3B;FTH1;...
Spliceosome 2.03 0.00e+0 101/150 (67.33%) HSPA6;HSPA1A;SMNDC1;...
IL-17 signaling pathway 1.99 4.05e-3 84/94 (89.36%) MMP1;S100A9;S100A8;...
Pertussis 1.98 3.38e-3 64/76 (84.21%) JUN;CXCL8;TICAM1;...
Staphylococcus aureus infection 1.97 2.89e-3 72/95 (75.79%) HLA-DQA1;C3;CFB;...
Mineral absorption 1.96 2.53e-3 48/60 (80%) HMOX1;MT1X;FTH1;...
Antigen processing and presentation 1.94 3.38e-3 60/78 (76.92%) HSPA6;HSPA1A;HLA-DQA1;...
Graft-versus-host disease 1.88 5.06e-3 32/42 (76.19%) HLA-DQA1;IL6;GZMB;...
Ribosome biogenesis in eukaryotes 1.87 4.60e-3 52/108 (48.15%) NXF1;LSG1;RPP40;...
Type I diabetes mellitus 1.79 1.60e-2 38/43 (88.37%) HLA-DQA1;GZMB;HSPD1;...
p53 signaling pathway 1.77 1.87e-2 63/73 (86.3%) GADD45A;SFN;CDKN1A;...
Inflammatory bowel disease 1.76 2.24e-2 58/65 (89.23%) JUN;HLA-DQA1;RORA;...
Lipid and atherosclerosis 1.71 3.65e-2 190/215 (88.37%) MMP1;HSPA6;HSPA1A;...
Nicotine addiction 1.69 4.05e-2 32/40 (80%) CACNA1A;GABRB1;GABRE;...
Intestinal immune network for IgA production 1.68 4.05e-2 38/48 (79.17%) HLA-DQA1;CXCR4;CXCL12;...
Terpenoid backbone biosynthesis -1.94 1.98e-2 18/22 (81.82%) ACAT2;ACAT1;ICMT;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H